Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer.
暂无分享，去创建一个
Y. Koh | N. Yamamoto | Y. Ozawa | H. Akamatsu | N. Tokudome | K. Mori | Masanori Tanaka | A. Hayata | R. Shibaki | S. Teraoka | J. Oyanagi | E. Murakami | T. Sugimoto | T. Kaki | Y. Harutani | E. Takase | Nao Yamagata | Yuka Okuda | K. Furuta